2026年

March 25, 2026: KYORIN Enter into Distribution and Promotion Agreement with Johnson & Johnson for SIRTURO
March 23, 2026: KYORIN and UBE Enter into License Agreement for Novel Drug Candidates
February 26, 2026: Notice Regarding the Introduction of a Mandate-Based Corporate Officer System and Changes in Corporate Officers
February 4, 2026: KYORIN Receives Regulatory Approval for influenza virus nucleic acid kit, GeneSoC FluAB Detection Kit
February 4, 2026: Consolidated Financial Results for the Nine Months Ended December 31, 2025 - Supplementary Information
February 4, 2026: Consolidated Financial Results for the Nine Months Ended December 31, 2025 [Japanese GAAP]
January 5, 2026: KYORIN and Lunatus Enter into Distribution Agreement for Lasvic Tablets in Nine Middle Eastern Countries